secwatch.observer — SEC 8-K summary
======================================

Issuer:     4D Molecular Therapeutics, Inc. (FDMT)
CIK:        0001650648
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0000950170-24-093992
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

4DMT reports Q2 net loss $35M, cash $578M; positive 4D-150 interim data; FDA lifts clinical hold on 4D-310
--------------------------------------------------------------------------------

- Cash and equivalents $578M as of June 30, 2024; expected to fund operations into H1 2027.
- Q2 net loss $35.0M vs $29.6M YoY; R&D expenses rose to $31.9M from $23.6M.
- Phase 2 PRISM 4D-150 in wet AMD: 89% reduction in annualized anti-VEGF injections; 77% injection-free at 24 weeks with 3E10 vg/eye dose.
- FDA removed clinical hold on Phase 1/2 INGLAXA trial for 4D-310 in Fabry disease cardiomyopathy; enrollment to resume H2 2024.
- Senior leadership added: Dhaval Desai (CDO), Christopher Simms (CCO), Carlos Quezada-Ruiz (SVP Ophth); Ophthalmology Advisory Board formed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1650648/000095017024093992/0000950170-24-093992-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1650648/000095017024093992/fdmt-20240808.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-093992

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer